Published in J Infect Dis on February 15, 2008
Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ (2011) 1.61
Retracted Immunopathology and immunogenetics of allergic bronchopulmonary aspergillosis. J Allergy (Cairo) (2011) 1.44
Toll-like receptor 9-dependent immune activation by unmethylated CpG motifs in Aspergillus fumigatus DNA. Infect Immun (2008) 1.30
Innate immunity to Aspergillus species. Clin Microbiol Rev (2009) 1.19
TLR9 is actively recruited to Aspergillus fumigatus phagosomes and requires the N-terminal proteolytic cleavage domain for proper intracellular trafficking. J Immunol (2010) 1.18
The microbiology of asthma. Nat Rev Microbiol (2012) 1.14
Toll-like receptor 9 modulates immune responses to Aspergillus fumigatus conidia in immunodeficient and allergic mice. Infect Immun (2008) 1.07
Genetic Susceptibility to Fungal Infections in Humans. Curr Fungal Infect Rep (2011) 1.04
Fungal allergy in asthma-state of the art and research needs. Clin Transl Allergy (2014) 1.03
Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. J Infect Dis (2011) 1.02
Dectin-1 and DC-SIGN polymorphisms associated with invasive pulmonary Aspergillosis infection. PLoS One (2012) 1.00
The Y238X stop codon polymorphism in the human β-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. J Infect Dis (2011) 0.99
Immunomodulatory parasites and toll-like receptor-mediated tumour necrosis factor alpha responsiveness in wild mammals. BMC Biol (2009) 0.97
The rs5743836 polymorphism in TLR9 confers a population-based increased risk of non-Hodgkin lymphoma. Genes Immun (2011) 0.92
Association of Single Nucleotide Polymorphisms in Toll-like Receptor Genes With Asthma Risk: A Systematic Review and Meta-analysis. Allergy Asthma Immunol Res (2014) 0.92
Fungal pathogens-a sweet and sour treat for toll-like receptors. Front Cell Infect Microbiol (2012) 0.92
Non-hematopoietic cells contribute to protective tolerance to Aspergillus fumigatus via a TRIF pathway converging on IDO. Cell Mol Immunol (2010) 0.91
Influence of polymorphisms in innate immunity genes on susceptibility to invasive aspergillosis after stem cell transplantation. PLoS One (2011) 0.91
Pattern recognition receptors in antifungal immunity. Semin Immunopathol (2014) 0.90
Toll-like receptor 9 modulates macrophage antifungal effector function during innate recognition of Candida albicans and Saccharomyces cerevisiae. Infect Immun (2011) 0.90
Genetic variation of innate immune genes in HIV-infected african patients with or without oropharyngeal candidiasis. J Acquir Immune Defic Syndr (2010) 0.90
The C allele of rs5743836 polymorphism in the human TLR9 promoter links IL-6 and TLR9 up-regulation and confers increased B-cell proliferation. PLoS One (2011) 0.90
Comprehensive genetic assessment of a functional TLR9 promoter polymorphism: no replicable association with asthma or asthma-related phenotypes. BMC Med Genet (2011) 0.89
Single nucleotide polymorphisms of Toll-like receptors and susceptibility to infectious diseases. Clin Exp Immunol (2015) 0.89
The role of TLR4 896 A>G and 1196 C>T in susceptibility to infections: a review and meta-analysis of genetic association studies. PLoS One (2013) 0.87
Striking a balance: fungal commensalism versus pathogenesis. Curr Opin Microbiol (2013) 0.86
The role of dendritic cells in the innate recognition of pathogenic fungi (A. fumigatus, C. neoformans and C. albicans). Virulence (2012) 0.86
Toll-like receptor 9 gene mutations and polymorphisms in Japanese ulcerative colitis patients. World J Gastroenterol (2010) 0.85
The cell biology of the innate immune response to Aspergillus fumigatus. Ann N Y Acad Sci (2012) 0.84
Human genetic susceptibility to invasive aspergillosis. PLoS Pathog (2013) 0.84
Allergic Bronchopulmonary Aspergillosis: A Perplexing Clinical Entity. Allergy Asthma Immunol Res (2016) 0.83
Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract (2014) 0.81
Paving the way for predictive diagnostics and personalized treatment of invasive aspergillosis. Front Microbiol (2015) 0.81
Mannose-binding lectin genotype and serum levels in patients with chronic and allergic pulmonary aspergillosis. Int J Immunogenet (2012) 0.80
Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium. Infect Immun (2015) 0.79
TLR9 activation dampens the early inflammatory response to Paracoccidioides brasiliensis, impacting host survival. PLoS Negl Trop Dis (2013) 0.79
Assessment of Toll-like receptor 2, 4 and 9 SNP genotypes in canine sino-nasal aspergillosis. BMC Vet Res (2014) 0.78
What are fungal infections? Mediterr J Hematol Infect Dis (2011) 0.78
Optimizing Outcomes in Immunocompromised Hosts: Understanding the Role of Immunotherapy in Invasive Fungal Diseases. Front Microbiol (2015) 0.78
Rapid detection of functional gene polymorphisms of TLRs and IL-17 using high resolution melting analysis. Sci Rep (2017) 0.78
Impaired Innate COPD Alveolar Macrophage Responses and Toll-Like Receptor-9 Polymorphisms. PLoS One (2015) 0.77
Polymorphism in the promoter region of the Toll-like receptor 9 gene and cervical human papillomavirus infection. J Gen Virol (2013) 0.77
TLR4 +896A>G (Asp299Gly) polymorphism is not associated with asthma: a update meta-analysis. Int J Clin Exp Med (2014) 0.76
Association of TLR4 (896A/G and 1196C/T) Gene Polymorphisms with Asthma Risk: A Meta-Analysis. Med Sci Monit (2015) 0.76
Previously Unidentified Single Nucleotide Polymorphisms in HIV/AIDS Cases Associate with Clinical Parameters and Disease Progression. Biomed Res Int (2016) 0.75
Co-colonisation with Aspergillus fumigatus and Pseudomonas aeruginosa is associated with poorer health in cystic fibrosis patients: an Irish registry analysis. BMC Pulm Med (2017) 0.75
Editorial: An Omics Perspective on Fungal Infection: Toward Next-Generation Diagnosis and Therapy. Front Microbiol (2017) 0.75
eMERGE Phenome-Wide Association Study (PheWAS) identifies clinical associations and pleiotropy for stop-gain variants. BMC Med Genomics (2016) 0.75
Allergic Bronchopulmonary Aspergillosis Presenting as Recurrent Mass-like Consolidation. Tuberc Respir Dis (Seoul) (2015) 0.75
Evaluation of Serum Aspergillus-Specific Immunoglobulin A by Indirect ELISA for Diagnosis of Feline Upper Respiratory Tract Aspergillosis. J Vet Intern Med (2016) 0.75
Genetic susceptibility to allergic bronchopulmonary aspergillosis in asthma: a genetic association study. Allergy Asthma Clin Immunol (2016) 0.75
Association of polymorphisms in TLR2 and TLR4 with asthma risk: An update meta-analysis. Medicine (Baltimore) (2017) 0.75
Association of Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile with the risk of primary open angle glaucoma. Graefes Arch Clin Exp Ophthalmol (2017) 0.75
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice. EMBO J (1995) 3.48
Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis (2005) 3.31
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother (1997) 2.99
Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans. Implications for initiation of T helper cell immunity in vitro and in vivo. J Exp Med (2000) 2.99
Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 2.79
Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology (2007) 2.49
Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother (1990) 2.49
High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother (1994) 2.21
The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol (2005) 2.21
Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int J Tuberc Lung Dis (2004) 2.20
Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach. J Infect (1993) 2.10
Interleukin-4 and interleukin-10 inhibit nitric oxide-dependent macrophage killing of Candida albicans. Eur J Immunol (1993) 2.05
Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother (1998) 2.04
Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy (2013) 2.03
Antifungal drug resistance in Aspergillus. J Infect (2000) 2.01
Fluconazole-resistant candidosis in an HIV cohort. AIDS (1994) 1.95
Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J (2010) 1.87
Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol (2001) 1.85
Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology (1994) 1.82
Invasive aspergillosis in patients with AIDS. Clin Infect Dis (1994) 1.80
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect (2003) 1.79
IL-22 defines a novel immune pathway of antifungal resistance. Mucosal Immunol (2010) 1.76
A mannoprotein constituent of Candida albicans that elicits different levels of delayed-type hypersensitivity, cytokine production, and anticandidal protection in mice. Infect Immun (1994) 1.68
Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular accumulation of drug. FEMS Microbiol Lett (1995) 1.66
Molecular typing by random amplification of polymorphic DNA and M13 southern hybridization of related paired isolates of Aspergillus fumigatus. J Clin Microbiol (1996) 1.65
Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (2002) 1.61
Th1 and Th2 cytokines in mice with invasive aspergillosis. Infect Immun (1997) 1.61
Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis (2015) 1.61
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis (1992) 1.58
Invasive infection due to penicillium species other than P. marneffei. J Infect (2002) 1.58
Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice. Infect Immun (1989) 1.56
Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections. Lab Anim (2003) 1.53
Multicenter comparative evaluation of six commercial systems and the national committee for clinical laboratory standards m27-a broth microdilution method for fluconazole susceptibility testing of Candida species. J Clin Microbiol (2002) 1.51
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther (1996) 1.51
In-vitro activity of the new triazole D0870 compared with amphotericin B and itraconazole against Aspergillus spp. J Antimicrob Chemother (1993) 1.51
Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother (2000) 1.50
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
Chronic obstructive pulmonary disease prevalence in Lisbon, Portugal: the burden of obstructive lung disease study. Rev Port Pneumol (2013) 1.49
T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol (2000) 1.48
Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis (2001) 1.48
Peripheral symmetrical gangrene successfully treated with epoprostenol and tissue plasminogen activator. Lancet (1986) 1.44
Aspergillus fungemia: report of two cases and review. Clin Infect Dis (1995) 1.42
New and emerging treatments for fungal infections. J Antimicrob Chemother (2008) 1.42
T helper cell type 1 (Th1)- and Th2-like responses are present in mice with gastric candidiasis but protective immunity is associated with Th1 development. J Infect Dis (1995) 1.41
Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis (1991) 1.40
Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp. Antimicrob Agents Chemother (1997) 1.39
Interleukin 18 restores defective Th1 immunity to Candida albicans in caspase 1-deficient mice. Infect Immun (2000) 1.39
Endemic mycoses: a treatment update. J Antimicrob Chemother (1999) 1.39
Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis (1998) 1.39
Performance of cryptococcus antigen latex agglutination kits on serum and cerebrospinal fluid specimens of AIDS patients before and after pronase treatment. J Clin Microbiol (1991) 1.38
Endogenous interleukin 4 is required for development of protective CD4+ T helper type 1 cell responses to Candida albicans. J Exp Med (1998) 1.37
CADRE: the Central Aspergillus Data REpository. Nucleic Acids Res (2004) 1.36
Azole resistance in allergic bronchopulmonary aspergillosis and Aspergillus bronchitis. Clin Microbiol Infect (2009) 1.32
Amphotericin B resistance testing of Candida spp.: a comparison of methods. J Antimicrob Chemother (1997) 1.32
Administering amphotericin B--a practical approach. J Antimicrob Chemother (1994) 1.32
Aspergillus wound infection following laparostomy. J Infect (1996) 1.31
Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother (2008) 1.31
Invasive yeast infections other than Candida spp. in acute leukaemia. J Hosp Infect (1999) 1.29
T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice. J Immunol (1990) 1.29
Role of nitric oxide and melanogenesis in the accomplishment of anticryptococcal activity by the BV-2 microglial cell line. J Neuroimmunol (1995) 1.28
Acute myelopathy associated with primary infection with human immunodeficiency virus. Br Med J (Clin Res Ed) (1987) 1.28
Antifungal type 1 responses are upregulated in IL-10-deficient mice. Microbes Infect (1999) 1.27
Molecular genetics in Aspergillus fumigatus. Curr Opin Microbiol (2000) 1.27
Interleukin-4 and -10 exacerbate candidiasis in mice. Eur J Immunol (1995) 1.27
In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J Antimicrob Chemother (1998) 1.27
Pathogenicity of Aspergillus fumigatus mutants assessed in Galleria mellonella matches that in mice. Med Mycol (2010) 1.26
Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother (2006) 1.26
Scedosporium prolificans, a multi-resistant fungus, from a U.K. AIDS patient. J Infect (1995) 1.23
In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis. Antimicrob Agents Chemother (2000) 1.21
Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol (2009) 1.20
In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp. Antimicrob Agents Chemother (1998) 1.19
Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis (1999) 1.19
Post-operative aspergillosis. Clin Microbiol Infect (2006) 1.19
Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis (1997) 1.19
Cure of murine candidiasis by recombinant soluble interleukin-4 receptor. J Infect Dis (1994) 1.19
Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy (2009) 1.18
CD4+ T-helper-cell responses in mice with low-level Candida albicans infection. Infect Immun (1996) 1.18
Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med (1995) 1.17
Chromosomal, epigenetic and microRNA-mediated inactivation of LRP1B, a modulator of the extracellular environment of thyroid cancer cells. Oncogene (2010) 1.16
Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob Agents Chemother (1996) 1.15
Interlaboratory reproducibility of a microsatellite-based typing assay for Aspergillus fumigatus through the use of allelic ladders: proof of concept. Clin Microbiol Infect (2009) 1.15
Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus. Infect Immun (1996) 1.14
In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother (1998) 1.14
Atypical eumycetoma caused by Phialophora parasitica successfully treated with itraconazole and flucytosine. Br J Dermatol (1997) 1.13
NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. Gastroenterology (2000) 1.13
Dynamics of extracellular release of Aspergillus fumigatus DNA and galactomannan during growth in blood and serum. J Med Microbiol (2009) 1.13
A TH1-TH2-like switch in candidiasis: new perspectives for therapy. Trends Microbiol (1995) 1.12
Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother (1999) 1.12
Immunity to fungi: editorial overview. Res Immunol (1998) 1.12
IFN-gamma is required for IL-12 responsiveness in mice with Candida albicans infection. J Immunol (1998) 1.12
Species differentiation by internally transcribed spacer PCR and HhaI digestion of fluconazole-resistant Candida krusei, Candida inconspicua, and Candida norvegensis strains. J Clin Microbiol (1997) 1.11
Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methods. Antimicrob Agents Chemother (2004) 1.10
Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother (2001) 1.10